Company Market Research Report

Company Overview

• Name: Lunit Inc.

• Mission: Saving lives through technology by utilizing AI for cancer detection and treatment.

• Founded: 2013

• Founders: No information is available

• Key People:

• Beomseok Brandon Suh – Chief Executive Officer

• Anthony Paek – Co-founder, Executive Chairman

• Hyeonseong Park – Chief Financial Officer

• Donggeun Yoo – Co-founder, Chief of Research

• Sunggyun Park – Co-founder, Chief Product, and Regulation Division Officer

• Kihwan Kim – Chief Medical Officer, Group Head of Cancer Screening Group

• Kyunghyun Paeng – Co-founder, Chief Product Officer, Oncology Group

• Chan-Young Ock – Chief Medical Officer, Oncology Group

• Ken Nesmith – Chief Business Officer, Group Head of Oncology Group

• Teri Thomas – Chief Business Officer, Cancer Screening Group

• Richard Yoo – Chief Technology Officer, Technology Innovation Group

• Jungin Lee – Co-founder, VP of Infrastructure

• Thijs Kooi – Dept. Head of Research, Cancer Screening Group

• Soochul Bang – Dept. Head of Software Development, Cancer Screening Group

• Yoonjin Kim – Dept. Head of Regulation

• Jaehoon Ahn – Dept. Head of Enhancement Engineering

• JaeMin Oh – Dept. Head of Business Development, Cancer Screening Group

• Yuchung Janice Jung – Dept. Head of Business Development, Cancer Screening Group

• Simon Sanghyup Lee – Dept. Head of Medical Affairs Department, Cancer Screening Group

• Sergio Pereira – Dept. Head of Research, Oncology Group

• Chang Ho Ahn – Dept. Head of Medical Affairs, Oncology Group

• Jeongseok Kang – Dept. Head of Software Development, Oncology Group

• Terri Kim - Dept. Head of Strategy, US Market, Oncology Group

• Ryan Choi – Dept. Head of Clinical Research, Cancer Screening Group

• Weicheng Wang – Dept. Head of AI Platform, Research Division

• Hyungah Kim – Dept. Head of People

• Jinsub Bae – Dept. Head of Finance & Accounting

• Siraj Ali – Dept. Head of Translational Medicine

• Sherry Kan – Dept. Head of Product Management & Marketing Dept.

• Mee Jeong Kang – Dept. Head of Product Management Dept., Cancer Screening Group

• Headquarters: Seoul, South Korea

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: AI-powered solutions for cancer diagnostics and therapeutics, particularly for breast cancer screening and cancer biomarker technologies.

Products

Radiology Products

Lunit INSIGHT CXR

• Description: AI-powered software for chest X-ray analysis.

• Key Features:

• Detects 10 abnormal radiologic findings with 97-99% accuracy.

• Provided accuracy for tuberculosis screening on chest X-ray images.

Lunit INSIGHT CXR Triage

• Description: AI-driven triage solution for emergency chest X-rays.

• Key Features:

• Prioritizes cases with critical conditions such as pleural effusion and pneumothorax.

• Developed to optimize workflow and reduce the reading time for radiologists.

Lunit INSIGHT MMG

• Description: AI solution for mammography.

• Key Features:

• Detects lesions suspicious of breast cancer with 96% AUC.

• Enhances diagnostic accuracy for dense tissues and supports density assessment.

Lunit INSIGHT DBT

• Description: AI software for digital breast tomosynthesis.

• Key Features:

• Quantifies lesion malignancy likelihood and supports various integration types.

• Improves reading performance, highlighting lesions with an abnormality score.

Oncology Products

Lunit SCOPE IO

• Description: AI-powered biomarker for immune phenotyping.

• Key Features:

• Classifies immune phenotypes in H&E slides within three days.

• Supports 16 cancer types and detects TILs from whole slide images.

Lunit SCOPE PD-L1

• Description: AI-powered PD-L1 biomarker analyzer.

• Key Features:

• Detects and quantifies PD-L1 expression with reduced interpretation discrepancy among pathologists.

• Provides visual reporting and supports reading efficiency in evaluating immunotherapy response.

Recent Developments

Acquisition

• Lunit Completes Acquisition of Volpara Health:

• Date: May 22, 2024

• Impact:

• Enhanced breast cancer screening capabilities.

• Enabled robust entry into the American market.

• Strengthened the mission to lead the global fight against cancer.

New Products and Features

• New Product: No new specific product mentioned.

• Recent Features Added:

• Integration of Volpara’s breast health platform with Lunit’s AI-powered solutions for breast cancer detection.

• Development of autonomous AI models to independently screen, detect, and diagnose cancer.

Partnerships

• Partnerships:

• Lunit Joins Roche's Digital Pathology Open Environment to advance cancer biomarker testing.

Research and Publications

• New Research Highlights:

• Publications on applications of AI in various cancer types, including studies featured in top journals like the Journal of Clinical Oncology, The LANCET Digital Health, and JAMA Oncology.

• Notable studies on immune phenotype mapping and AI-based diagnostics, such as predictions in immune checkpoint inhibitor responses and early cancer detection.